Urolithiasis pp 801-803 | Cite as

Combined Hydrochlorothiazide and Magnesium Treatment in Calcium-Oxalate Stone Formers — A Randomized Study

  • C. Ahlstrand
  • H.-G. Tiselius
  • K. Sandvall

Abstract

Since the first reports of Yendt and co-workers (1) thiazides have been used in the prevention of recurrent renal calculi. During recent years, some controlled studies have shown a protective effect of thiazides (2, 3) whereas others have not (4, 5). A similar constroversy exists concerning the effects of magnesium treatment where two controlled studies (3, 6), in contrast to previous reports (7), failed to show any protective effect of magnesium.

Keywords

Stone Formation Calcium Oxalate Magnesium Hydroxide Urine Composition Magnesium Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    ER Yendt, GF Guay, and DA Garcia, The use of thiazides in the prevention of renal calculi, Can. Med. Assoc. J. 102:614 (1970).PubMedGoogle Scholar
  2. 2.
    E Laerum, Thizide prophylaxis of urolithiasis: a double blind study in general practice, Scand. J. Urol. Nephrol. Suppl. 80:70 (1983).Google Scholar
  3. 3.
    B Ettinger, JT Citron, B Livermore, and LI Dolman, Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not, J. Urol. 139:679 (1988).PubMedGoogle Scholar
  4. 4.
    P Brocks, C Dahl, H Wolf, and I Transböl, Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 1:24 (1981).Google Scholar
  5. 5.
    D Scholz, PO Schwille, and A Siegal, Double-blind study with thiazides in recurrent calcium lithiasis, J. Urol. 128:903 (1982).PubMedGoogle Scholar
  6. 6.
    DR Wilson, AL Strauss, and MA Manuel, Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis, Urol. Res. 12:39 (1984).Google Scholar
  7. 7.
    G Johansson, U Backman, BG Danielson, B Fellström, S Ljunghall, and B Wikström, Biochemical and clinical effects of the prophyactic treatment of renal calcium stones with magnesium hydroxide, J. Urol. 124:770 (1980).PubMedGoogle Scholar
  8. 8.
    C Ahlstand and H-G Tiselius, Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease, J. Urol. 126:635 (1981).Google Scholar
  9. 9.
    H-G Tiselius, C Ahlstrand, and L Larsson, Urine composition in patients with urolithiasis during treatment with magnesium oxide, Urol. Res. 8:197 (1980).PubMedCrossRefGoogle Scholar
  10. 10.
    C Ahlstrand and H-G Tiselius, Biochemical effects in patients with calcium oxalate stone disease during combined therapy with bendroflumethiazide and magnesium oxide, Br. J. Urol. 56:125 (1983).CrossRefGoogle Scholar
  11. 11.
    H-G Tiselius, An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease, Clin. Chim. Acta 122:409 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • C. Ahlstrand
    • 1
  • H.-G. Tiselius
    • 1
  • K. Sandvall
    • 1
  1. 1.Department of UrologyUniversity HospitalLinköpingSweden

Personalised recommendations